Full-Time

Scientist - Lipid Nanoparticle Delivery

Posted on 9/9/2025

NewLimit

NewLimit

51-200 employees

Develops epigenetic medicines to extend healthspan

Compensation Overview

$113k - $185k/yr

San Bruno, CA, USA

In Person

Category
Biology & Biotech (2)
,
Requirements
  • Ph.D. in Biomedical Engineering, Chemical Biology, Chemical Engineering, or a related discipline or ≥5 years of equivalent industry experience
  • Experience formulating lipid nanoparticles with diverse lipid components for nucleic acid delivery
  • Experience evaluating lipid nanoparticle quality based on size, nucleic acid loading efficiency, and polydispersity
  • Experience with LNP delivery either in vitro or in vivo and associated reporter read-outs
Responsibilities
  • Collaborate with our Epigenetic Editing and Metabolism teams to design and implement an LNP delivery strategy for reprogramming interventions
  • Formulate lipid nanoparticles for nucleic acid delivery to hepatocytes in a variety of model systems, including humanized liver models
  • Engineer lipid nanoparticles with targeting moieties to promote cell type-specific delivery
  • Serve as the key decision maker for NewLimit’s lipid nanoparticle formulation approach at the Discovery stage
  • Analyze and interpret experimental data to drive decision making in Discovery and pre-clinical Development
Desired Qualifications
  • History of contributing to a drug development program at the pre-clinical or clinical development stage
  • Experience with LNP delivery to hepatocytes or a background in liver biology
  • Experience modifying LNPs with targeting moieties to engender cell type specificity
  • Experience with next-generation sequencing (NGS) and high-throughput experimental systems

NewLimit develops medicines that aim to extend healthy years by reprogramming the epigenome of aging cells. It works by identifying aging-related epigenetic changes using single-cell genomics, machine learning, and high-throughput functional assays, then creating interventions to reverse those changes in targeted tissues such as the immune system and liver. Compared with others, NewLimit combines a specific focus on epigenetic reprogramming with a data-driven, tissue-targeted pipeline and pursues partnerships with pharma and biotech players to develop its proprietary medicines. Its goal is to deliver a new class of medicines that significantly increases the healthspan for patients with age-related diseases.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$215M

Headquarters

South San Francisco, California

Founded

2022

Simplify Jobs

Simplify's Take

What believers are saying

  • Raised $45M from Eli Lilly at $1.62B valuation in late 2025.
  • Achieved 2 prototype liver medicines efficacious in preclinical models by August 2025.
  • Conducting IND-enabling studies for liver-rejuvenating mRNA as of February 2026.

What critics are saying

  • FDA rejects liver IND due to animal safety signals within 6-12 months.
  • Eli Lilly withdraws support after preclinical failures in 12-18 months.
  • Retro Biosciences captures first-mover advantage in 12-24 months.

What makes NewLimit unique

  • NewLimit reprograms epigenomes using single-cell genomics and machine learning.
  • Targets hepatocytes, T cells, and endothelial cells for age-related diseases.
  • Develops LNP-mRNA payloads restoring youthful function without cell type change.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Parental Leave

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

-1%

2 year growth

2%
Intellectia.AI
Jan 6th, 2026
Coinbase CEO Armstrong's NewLimit raises $45M at $1.62B valuation for anti-aging research

NewLimit, an anti-aging startup founded in 2021 by Coinbase CEO Brian Armstrong, has raised $45 million in new funding, valuing the company at $1.62 billion. The round comes just five months after its Series B, demonstrating rapid growth and strong investor confidence. The company focuses on extending human healthspan by treating age-related diseases. The fresh capital will support groundwork for future clinical studies to advance its technological capabilities. Competition in the longevity sector is intensifying, with OpenAI CEO Sam Altman investing $180 million in rival Retro Biosciences. Despite a 2025 downturn in anti-aging research stocks, NewLimit's successful funding round highlights investor belief in the sector's long-term potential and suggests continued capital flow into this emerging market.

NewLimit
Oct 22nd, 2025
NewLimit has raised an additional $45M from Lilly, Duke University, Section 32, & Abstract on a $1.62B cap

Five months after closing our Series B, NewLimit has raised an additional $45M from Eli Lilly and Company, Duke Management Co, Section 32, and others on a $1.62B cap.

Endpoints News
Oct 20th, 2025
NewLimit Raises $45M with Eli Lilly

NewLimit, an anti-aging biotech startup co-founded by a cryptocurrency billionaire, has raised $45 million from new investors, including Eli Lilly. This funding positions NewLimit to potentially become biotech's latest unicorn.

TradingView
May 15th, 2025
NewLimit Raises $129.8M in Equity Financing

NewLimit has successfully raised $129.8 million in equity financing from a total offering amount of $130 million.

NewLimit
May 7th, 2025
NewLimit raises $130 million Series B led by Kleiner Perkins alongside NFDG, Khosla Ventures, Human Capital and others

NewLimit is developing medicines to extend human healthspan through epigenetic reprogramming

INACTIVE